Welcome, ladies and gentlemen, to AstraZeneca's full-year and Q4 2024 results conference call for investors and analysts.

Second interim dividend declared of $2.10 per share, making a total annual dividend declared for FY 2024 of $3.10 per share, an increase of 7%. Di ...

AstraZeneca (NASDAQ:AZN) shares gained in European trading on Thursday after the Anglo-Swedish drugmaker reported better-than-expected Q4 2024 results and addressed investor concerns over an ...

Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...

Reports Q4 reported EPS 97c vs. 62c last year. Reports Q4 revenue $14.89B, consensus $14.28B. Pascal Soriot, CEO, AstraZeneca (AZN), ...

In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company ...

A fresh earnings release was the news development powering AstraZeneca's (NASDAQ: AZN) share price higher on Thursday.

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business ...

Reports Q4 revenue $14.89B, consensus $13.34B. The company said, “Our company delivered a very strong performance in 2024 with Total Revenue ...